Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study

scientific article published on 23 August 2014

Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.AUTREV.2014.08.023
P698PubMed publication ID25183232

P50authorGiovanni VeronesiQ41098833
P2093author name stringArmando Gabrielli
Francesco Logullo
Maria Giovanna Danieli
Lucia Pettinari
Simona Gambini
P433issue10
P921main subjectdermatomyositisQ681160
immunologyQ101929
P304page(s)1048-1054
P577publication date2014-08-23
P1433published inAutoimmunity ReviewsQ15754966
P1476titleImpact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study
P478volume13

Reverse relations

cites work (P2860)
Q864215047th International Immunoglobulin Conference: Immunomodulation
Q99574672AST/ALT ratio as a predictor of mortality and exacerbations of PM/DM-ILD in 1 year-a retrospective cohort study with 522 cases
Q90717828Analysis of myositis autoantibodies in Chinese patients with cancer-associated myositis
Q39776324Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease
Q40391930Cardiac Abnormalities in Adult Patients With Polymyositis or Dermatomyositis as Assessed by Noninvasive Modalities.
Q47425244Cardiac function in patients with polymyositis or dermatomyositis: a three-dimensional speckle-tracking echocardiography study.
Q37699967DEPTOR-mTOR Signaling Is Critical for Lipid Metabolism and Inflammation Homeostasis of Lymphocytes in Human PBMC Culture.
Q37615001Identification of Palmitoleic Acid Controlled by mTOR Signaling as a Biomarker of Polymyositis
Q30252086Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review
Q51835838Immune-Mediated Heart Disease.
Q26765226Intravenous Immunoglobulins: Mode of Action and Indications in Autoimmune and Inflammatory Dermatoses
Q33419638Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe
Q40901486Long-term follow-up of 124 patients with polymyositis and dermatomyositis: Statistical analysis of prognostic factors
Q40069189Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain
Q92068013Polymyositis/dermatomyositis is a potential risk factor for acute respiratory failure: a pulmonary heart disease
Q47436112Recent developments on treatment strategies and the prognosis of dermatomyositis: a review
Q89677872Recovering autonomy is a key advantage of home-based immunoglobulin therapy in patients with myositis: A qualitative research study
Q90176667Reduced miR-146a Promotes REG3A Expression and Macrophage Migration in Polymyositis and Dermatomyositis
Q38824186The potential of intravenous immunoglobulins for cancer therapy: a road that is worth taking?
Q90318717[Dermatomyositis and rectal cancer: case study and literature review]

Search more.